Activation and Abnormalities of Cell Cycle Regulating Factor in Head and Neck Squamous Cell Carcinoma Cell Lines: Abnormal Expression of CDKN2 Gene in Laryngeal Squamous Cell Carcinoma.
10.12701/yujm.2005.22.2.166
- Author:
Si Youn SONG
1
;
Tae Hee HAN
;
Chang Hoon BAI
;
Yong Dae KIM
;
Kei Won SONG
Author Information
1. Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Yeungnam University, Daegu, Korea. ssykhs@med.yu.ac.kr
- Publication Type:Original Article
- Keywords:
CDKN2;
Laryngeal cancer;
Loss of heterozygosity
- MeSH:
Alleles;
Arm;
Astrocytoma;
Carcinogenesis;
Carcinoma, Squamous Cell*;
Cell Cycle*;
Cell Line*;
Chromosomes, Human;
Colonic Neoplasms;
DNA;
Genes, p16*;
Glioma;
Head*;
Humans;
Laryngeal Neoplasms;
Leukemia;
Loss of Heterozygosity;
Lung Neoplasms;
Microsatellite Repeats;
Neck*;
Neuroblastoma;
Osteosarcoma;
Ovarian Neoplasms;
Phosphotransferases;
Polymerase Chain Reaction;
RNA, Messenger;
S Phase
- From:Yeungnam University Journal of Medicine
2005;22(2):166-182
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Cyclin-dependent kinase (CDK) inhibitors are family of molecules that regulate the cell cycle. The CDKN2, a CDK4 inhibitor, also called p16, has been implicated in human tumorigenesis. The CDKN2 inhibits the cyclin/CDK complexes which regulate the transition from G1 to S phase of cell cycle. There is a previous report that homozygous deletion of CDKN2 region on chromosome 9p21 was detected frequently in astrocytoma, glioma and osteosarcoma, less frequently in lung cancer, leukemia and ovarian cancer, but not detected in colon cancer and neuroblastoma. However, little is known about the relationship between CDKN2 and laryngeal cancer. Therefore this study was initiated to investigate the role of CDKN2 in human laryngeal squamous cell carcinoma development. MATERIALS AND METHODS: We used 5 human laryngeal carcinoma cell lines whether they have deletions or losses of CDKN2 gene expression by DNA-PCR or RT-PCR, respectively. We examined 8 fresh frozen human laryngeal cancer tissues to detect the loss of heterozygosity (LOH) of CDKN2. PCR was performed by using microsatellite markers of short arm of human chromosome 9 (D9S126, D9S144, D9S156, D9S161, D9S162, D9S166, D9S171, D9S200 and D9SIFNA). For informative cases, allelic loss was scored if the signal of one allele was significantly decreased in tumor DNA when compared to the same allele in normal DNA. RESULTS: The CDKN2 DNA deletion was observed in 3 cell lines. The CDKN2 mRNA expression was observed in only one cell line, which was very weak. LOH was detected in 7 cases (87.5%). CONCLUSION: These results suggest that CDKN2 plays a role in the carcinogenesis of human laryngeal squamous cell carcinoma.
